Tag Archive for: Yellow Jersey Therapeutics

Novo Holdings portfolio company Numab Therapeutics announces Johnson & Johnson (‘J&J’) to acquire its wholly-owned subsidiary Yellow Jersey Therapeutics

Under the agreement terms, J&J will pay $1.25 billion to acquire Yellow Jersey Therapeutics, which holds NM26 rights, and will gain full rights to develop, manufacture and commercialize NM26 globally for the treatment of atopic dermatitis and follow-on indications NM26 is a Phase 2-ready bi-specific antibody from Numab’s pipeline of candidates discovered and engineered using […]